Document Detail


Cardiovascular diseases and the nitric oxide pathway.
MedLine Citation:
PMID:  15320480     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Fifteen years after its discovery, NO has fully reached an established position in physiology, medicine and therapeutics. It is difficult to find a biological function or a pathological condition where NO does not play a relevant role. Discoveries in the NO field have historically evolved from cardiovascular research, although its influences have already covered nearly all the medical specialties. This review analyzes, step by step, the pathway through which NO is synthesized in the cells of the cardiovascular system and the main physiological and pathological routes it undergoes once it is released. We focus on various diseases affecting the cardiovascular system (atherosclerosis, hypertension, diabetes mellitus and septic shock). We describe in detail those steps of the NO pathway in which anomalies have been detected and may account for the pathophysiology of these diseases. In atherosclerosis, hypertension and diabetes mellitus, the endothelial form of NOS is upregulated, but is very sensitive to environmental conditions, such as substrate or cofactor deficiencies or increases in LDL or glucose. In this situation NOS synthesizes superoxide anion instead of NO leading to oxidative and nitrosative stress. In diabetes mellitus and, very importantly, in septic shock, the inducible form of NOS is highly upregulated. Overproduction of NO appears to underlie the hypotension and tissue damage of septicemia and the destruction of beta-cells in diabetes mellitus. New knowledge of the role of NO in these diseases has started to influence therapeutic design. We also review the current status of research on NO-based therapies.
Authors:
Silvia Llorens; Eduardo Nava
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current vascular pharmacology     Volume:  1     ISSN:  1570-1611     ISO Abbreviation:  Curr Vasc Pharmacol     Publication Date:  2003 Oct 
Date Detail:
Created Date:  2004-08-23     Completed Date:  2004-12-01     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  101157208     Medline TA:  Curr Vasc Pharmacol     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  335-46     Citation Subset:  IM    
Affiliation:
University of Castilla La Mancha School of Medicine & Centro Regional de Investigaciones Biomedical Campus de Albacete 02006 Albacete, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Arginine / metabolism
Arteriosclerosis / metabolism
Cardiovascular Diseases / metabolism*
Cardiovascular System / metabolism
Diabetes Mellitus / metabolism
Humans
Hypertension / metabolism
Nitric Oxide / metabolism,  physiology*
Nitric Oxide Synthase / metabolism
Shock, Septic / metabolism
Chemical
Reg. No./Substance:
10102-43-9/Nitric Oxide; 74-79-3/Arginine; EC 1.14.13.39/Nitric Oxide Synthase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical perspectives on the role of anti-platelet and statin therapy in patients with vascular dise...
Next Document:  Large A-V fistula: pathophysiological consequences and therapeutic perspectives.